We assessed the morbidity and mortality of subjects with transiently elevated diastolic pressure in the General Practice Hypertension Study Group (GPHSG) population. A total of 23 578 patients (aged 18-65 years) from seven UK general practices were screened in 1974 for a diastolic blood pressure (DBP4) of X90 mmHg. Two further readings of DBP4 determined hypertensive (either DBP4X90 mmHg) or transient hypertensive (both DBP4o90 mmHg) status. Transients (n ¼ 850) were matched with normotensive controls (n ¼ 824) and risk ratios calculated over a mean follow-up of 18.7 years. Rescreening was conducted in six of the practices (n ¼ 20 942) after 7.7 years. Male transients had a higher relative hazard for cardiovascular mortality than controls (11.8%, 8.6%, adjusted relative hazard 1.59, P ¼ 0.056). Female transients had a lower relative hazard for cardiovascular mortality than controls (3.6%, 5.4%, adjusted relative hazard 0.39, P ¼ 0.018). In all, 422 patients with transient hypertension were rescreened along with 367 matched controls. Significantly more transients were on antihypertensive treatment compared with their controls (odds ratio (OR) [95% CI]) for both male (4.2 [1.6-11.1]) and female patients (2.4 [1.0-5.56]) and more untreated female transients developed hypertension. Male transients had a higher rates of diabetes mellitus (adj OR ¼ 5.1, P ¼ 0.04) and stroke (adj OR 15.9, P ¼ 0.03). This study has shown that transiently elevated DBP in GPHSG is associated with a significantly higher risk of later hypertension in men and women and of diabetes, stroke and cardiovascular mortality in men. Women with this condition have a significantly lower cardiovascular mortality.
Introduction
Screening patients for the presence of hypertension is complicated by the fact that blood pressure (BP) fluctuates from moment to moment depending upon a wide range of patient-and observer-related factors. Identification of raised BP is critically dependent on the criteria used including the threshold values, the equipment used, the number of readings at a given visit (or the mean value) and the number of occasions on which the BP is noted to be elevated. Furthermore, the white-coat effect is a recognised phenomenon, in which the subject's BP is transiently raised (or reduced) during BP measurement in surgeries and clinics. 1, 2 White-coat hypertension can be identified if repeated measurements show it to be transient or, if persistent, nonclinic measurements (home or ambulatory BP) are found to be normal. It has been shown to be greater in the presence of a doctor as opposed to a nurse. 3 A transiently raised BP may be a frequent finding. One study found that 21% of patients with untreated borderline hypertension had normal daytime ambulatory pressures, defined as below 134/90 mmHg. 4 In a number of hypertension trials, marked reductions occurred in the BP of patients in the placebo arm suggesting that the initial BP was transiently elevated in the measurements leading up to entry to the trial. [5] [6] [7] [8] [9] [10] In the Australian Therapeutic Trial, 48% of the placebo group, whose mean diastolic BP (DBP) at two screening visits was 95-109 mmHg, had DBPs below 95 mmHg after 3 years of placebo treatment. 5 More recently the patients in the placebo arm of the Syst-Eur Trial 7 had large falls in their BP over the first 2 years of the trial of 13 mmHg systolic and 2 mmHg diastolic. These were not associated with significant falls in their ambulatory BP.
While cardiovascular disease is strongly predicted by serial BP measurements, 11 it is not known whether or not it is associated with the white-coat effect. Cross-sectional studies have reported an increased incidence of precursors of cardiovascular disease such as left ventricular hypertrophy. [12] [13] [14] [15] [16] [17] However, prospective studies appear to offer the best opportunity in which to detect an effect and reported studies are divided into those who find that the white-coat effect has adverse consequences for cardiovascular disease [18] [19] [20] and those that find that it does not. 6, [21] [22] [23] [24] [25] [26] We have previously reported 11-year mortality data in the General Practice Hypertension Study Group (GPHSG) in subjects with transiently raised clinic DBP, and found the relative risk of cardiovascular death compared with controls was 1.5 in men and 0.7 in women compared to normotensive controls 27 but these results were not statistically significant. In this paper, we report the mortality over an 18.7-year period and also examine the association of transient hypertension with nonfatal events, biochemical indicators and subsequent development of hypertension at a resurvey of participants after a mean of 7.7 years.
Methods
The GPHSG was formed in 1974 by representatives of eight general practices. 28 The main objective was to screen all patients on the practice lists for hypertension who were aged between 18 and 65 years. The practice population included rural areas (Pontesbury and Eaton Socon), provincial towns (Rugby, Ipswich and Darlington) and suburban and inner city areas (East Kilbride, Eccles and Southall). The patients were either invited by letter to attend special screening clinics or their notes were identified and they were screened when attending the surgery for other reasons. Screening was performed by practice nurses who had been trained to use a random zero sphygmomanometer. Systolic blood pressure (SBP) and DBP phases IV and V were measured after resting for 5 min in the sitting position. Data were also recorded on medical conditions at examination, smoking history (current smoker, past smoker or never smoked), country of birth, ethnic group, height and weight. Hypertension was defined on the basis of DBP only, with a DBPo90 mmHg (phase IV) defining normotension. Normotensives were not recalled for repeat BP measurements. Patients with DBP (IV) values between 90 and 129 mmHg were rescreened on two further occasions, at least 1 month apart. If the DBP (IV) was less than 90 mmHg on both the subsequent visits, the patient was categorised as having a 'transient hypertension'. Patients with transient hypertension were matched with a normotensive control by age (within 2.5 years), sex, practice date of screen (within 1 year) and ethnic group (European, Afro-Caribbean and Asian from the Indian Subcontinent).
Between 1983 and 1988, the transient hypertensives and nonhypertensive controls were invited to be rescreened. Diagnoses of myocardial infarction (MI), angina, stroke, transient ischaemic attack (TIA), diabetes and gout were recorded, and BP and pulse were measured. In all, 99% of patients of the original cohorts were flagged with OPCS for mortality follow-up and death certificates were coded by trained staff using the International Classification of Diseases (ICD) (9th revision). The mortality results include deaths notified up to 1.9.97. A patient was considered to have had a fatal cardiovascular event if any of the cardiovascular diseases was stated on the death certificate as an underlying cause (MIICD 4100-4109, stroke ICD 4300-4349, 4360-4389). Seven of the eight general practices participated in the mortality study and six in the rescreening programme.
Current treatment was recorded as either 'present treatment for BP' or 'present treatment other than for BP'. A patient was considered to have a diagnosis of hypertension if they were prescribed a drug for hypertension. A patient was considered to be on hypotensive agents at the time of rescreen if there was any record of an antihypertensive drug, a betaadrenergic blocker a calcium channel blocker or a diuretic, regardless of the reason for prescription.
Differences between proportions were examined using the w 2 test and construction of confidence intervals. Differences in quantitative variables were examined using unpaired t-tests. The odds ratio (OR) for morbid events was derived from logistic regression analysis and was adjusted for SBP age, smoking and body mass index at baseline (first screen). We chose logistic regression since information on outcome was only available at one point in time (the rescreen date), dates of morbid events being recorded only approximately. Conversely, date of death was available with a high degree of accuracy (death certificates) and therefore the Cox proportional hazards method was used to analyse association between the covariates (the state of transient hypertension as opposed to matched controls, age, smoking status, body mass index and SBP) and survival time. The categorical variable of 'having transient hypertension or not' does not fully represent the effect of BP in these models and we therefore included SBP, which is associated strongly with cardiovascular morbidity and mortality in previous studies.
Results

Morbidity
A total of 23 578 patients were screened from the seven general practices that participated in the Table 1 gives descriptive data of the patients with transient hypertension and their controls who were rescreened. In all, 53% of controls and 59% of the cases (based on those who were alive at 1.1.83) were reassessed in the practices taking part in the rescreen. The average length of follow-up between the original screen and the rescreen was 7.7 years. Male transient hypertensives were significantly more likely to be prescribed a diuretic or other antihypertensive treatment. Similar trends were observed in women. Body mass index was higher for transients than controls at baseline and at rescreen in the cases of both male and female. There were no significant differences between hypertensives and controls in the proportion who were current smokers at rescreen. Blood glucose levels were significantly higher in transients than controls for both male and female and similar results
were found for cholesterol in men. However, there was no significant difference found between transients and controls for both blood urate and urea levels. Table 2 shows the mean BP at original screen (first measurement), the average value of the second and third visit and at rescreen irrespective of treatment at this time. Patients with transient hypertension had significantly higher pressures than controls for initial screen and for rescreen and this was true for systolic, phase 4 diastolic and phase 5 diastolic readings. As expected from the study protocol (see the Methods section), the subjects with transient hypertension had significantly higher first readings compared with the second and third visits. The latter readings were, however, significantly higher than those of the controls at their first (only) reading. At rescreen, the average BP in the transient hypertension group tended to be lower than their first screen readings and the reverse was true in the controls who had higher rescreen values.
The rescreen BP classification for transient hypertensives and controls was divided into four categories: untreated normotensive (SBPo160 and . However, for both men and women there was a statistically significant excess of use of hypertensive medication for transients over controls. The incidence of important nonfatal diagnoses from the original screen to the date of rescreen is shown in Table 4 . The incidence of diabetes was significantly higher in male transients (7.5%) compared with their controls (1.1%). A similar excess remained if patients on hypertensive treatment were excluded (6.6%, 1.1%). Adjusted logistic regression showed that this excess was statistically significant (adj OR 5.1, P ¼ 0.04). Male transients had significantly more strokes than their controls (adj OR 15.9, P ¼ 0.03). The total number of nonfatal cardiovascular complications was not significantly higher in men with transient hypertension than their controls (adj OR 1.9, P ¼ 0.14). The event rate was low in women such that adjusted logistic regression was not possible. Women with transient hypertension did not have an excess of transient ischaemic attacks and no woman developed stroke or gout. In all, 4.2% of men with transient hypertension developed gout against 2.2% in male controls (P ¼ 0.26) and these figures were unchanged when those treated for Mortality Table 5 gives the total number of deaths up to 1.9. 97. The number of cardiovascular deaths was higher in men with transient hypertension in comparison with their controls, but in women with transient hypertension fewer deaths were observed during the 18.7 years of follow-up. The table also shows the total number of deaths to 1.1.83 (when rescreening commenced) and the numbers of reports on these death certificates of cardiovascular diseases and diabetes. Table 6 shows the Cox proportional hazards analysis. When adjusted for age, smoking status, systolic BP and body mass index, the relative hazard rate ratio for male transients compared with their controls was 1.59 (P ¼ 0.056) and in women was 0.39 (P ¼ 0.018) for cardiovascular mortality. The corresponding results for all cause mortality were for males 1.33 (0.08) and for females 0.52 (0.009).
Discussion
Men with transient hypertension, after adjusting for age, smoking status, body mass index and initial SBP, tended to have a higher cardiovascular and all cause mortality than controls, whereas women with transient hypertension had significantly lower mortality. This finding is consistent with our previous report on mortality in this cohort 27 and reinforces the importance of identifying and following up transient elevations of the blood pressure, at least in men.
Other long-term studies of cardiovascular outcome of white-coat hypertension have produced conflicting results. However, it is notable that those which found an increased cardiovascular risk studied high-risk patients and predominantly male subjects. [18] [19] [20] Studies reporting no increase in risk examined patients who were drawn from the general population 6, 7 or which followed up for periods of time less than 10 years. 21, 23, 24, 26 In our own study, 11 years was insufficient for cardiovascular effects to be demonstrable with statistical significance. 27 Female subjects predominate in the subgroups identified as having a large white-coat effect. These obervations, taken together those of our study, are consistent with the hypothesis that whitecoat hypertension may be a significant risk factor if and only if cardiovascular risk is already elevated (by male sex, elevated blood glucose, relative excess in smoking rate). The implication of this is that if the overall risk is low then a patient with a marked white-coat effect can be reassured and followed up yearly to detect those who develop sustained hypertension, whereas an individual with existing risk factors and significant risk must be followed up and is likely to need treatment; whether this treatment should commence immediately or once hypertension is established is not known but given that the effects of hypertension are only partially reversed by treatment we would argue that it should start immediately.
Males with transient hypertension had a high and statistically significant OR for developing diabetes mellitus, which has been shown to increase cardiovascular risk, particularly where BP is not well controlled. 29 Epidemiological studies have found that glucose intolerance is more prevalent in hypertensives and that diabetics have an increased prevalence of hypertension. 30, 31 The tendency for an excess of gout in men was unlikely to be due entirely to diuretic therapy, as the relationship was seen in patients who had no record of receiving antihypertensive drugs. The male transient hypertensive group also had significantly higher body mass index levels compared with controls and survival and morbidity analyses were adjusted for body mass index. A positive association between obesity and SBP and DBP has commonly been reported. 32, 33 The increased morbidity of the group of transient hypertensives in this study is consistent with the increasing body of evidence supporting white-coat hypertension as a risk factor for cardiovascular disease. 14 Our data indicate that the reduced risk of female transients with respect to their controls is, if anything, a stronger relation than that for the increase in men and is present in both the cardiovascular and the all cause mortality data. The gender difference is not explained by differences in BP, either initially or at rescreen. Similarly, body mass index was higher in transient hypertensives than controls for both sexes at baseline and rescreen. Baseline glucose and cholesterol levels were not measured. The gender difference could be due to delay in cardiovascular risk coming through as women develop cardiovascular disease later and this is supported by the observations that the women transients at rescreen had higher rates of hypertension than their controls and that this was more marked than for the men and that the numbers of morbid events at rescreen were lower (and nonsignificant). However, it is not clear why female transients should be more affected by this than their controls. One possibility is that this is attributable to the higher rates of antihypertensive treatment in female transients than controls. However, this observation also implies a higher rate of hypertension and therefore higher cardiovascular risk and the BP at rescreen was higher for female transients than their controls.
It is also possible that the BP screening process itself resulted in a population of lower risk women. Firstly, it is known that the white-coat effect is more pronounced in women. 34 Secondly, in GPHSG there was a marked number preference for diatolic IV of '88 mmHg', which we have shown resulted in a high-risk cohort of controls with this screening BP, 35 perhaps depriving the group of 'transient hyperten- Patients with transient hypertension had higher BP than their controls at baseline and at rescreen and more developed hypertension than their controls. This placed both male and female patients with the condition in GPHSG at markedly high risk of developing cardiovascular disease. While phase IV BP were used in the original screen, this is unlikely to have distorted this conclusion since phase V readings and systolic readings show the same trends and at rescreen these constituted the standard method of measuring DBP.
The unadjusted rates of nonfatal cardiovascular events (defined as myocardial infarction, angina, stroke or transient ischaemic attack) tended to be higher in male and female transient hypertension subjects compared with their controls but was not statistically significant. However, the number of events overall was small to draw firm conclusions and indeed logistic regression analysis was not possible for the female group. The morbidity rates at rescreen could not take into account disease acquired by patients who died before rescreening took place. However, cardiovascular disease was the underlying cause of death for a larger proportion of male patients with transient hypertension than for women, suggesting that it is unlikely that early death has substantially distorted our findings (Table 5) . Diabetes was mentioned in part II of the death certificates of three of the 17 men with transient hypertension who died and in one of the controls. The morbidity for diabetes at rescreen may, therefore, have been underestimated.
We acknowledge that the manner of assessing transient BP elevation in this study does not mirror the current approach to detecting the white-coat effect, which involves assessing the difference between clinic BP and the daytime ambulatory BP or self-measurements by the patients. In our study, a high initial BP dropped to lower levels on the subsequent two screening visits consistent with regression to the mean. However, even at these subsequent visits the BP of transients remained higher than that of controls and were still higher at rescreen. For this reason comparison, albeit not exact, with the case of white-coat hypertension is justified.
In conclusion, our data suggest that transiently elevated DBP represents a state that is associated with higher risks of development of sustained hypertension. In men, it is associated with a tendency to increased risk in cardiovascular mortality as well as higher incidence of diabetes and stroke than in normotensives. In women, the cardiovascular mortality is significantly lower than controls. It is possible that as women age and the number of cardiovascular events increases, the disadvantage of transient hypertension will become apparent. Alternately, it is possible that this gender effect occurs in our study because the female patients are low risk and the white-coat effect has measurable consequences for cardiovasuclar disease only when the risk is high. We recommend that other epidemiological studies of transient hypertension examine their results for a gender difference in outcome (Table 7) . Table 7 Contribution of this paper to the understanding of white coat hypertension What is known on this topic Transient hypertension is variously defined but is a common phenomenon Long-term studies suggests that transiently elevated blood pressure may be a risk factor for cardiovascular disease What this paper adds Transiently elevated blood pressure is associated with increase risk of hypertension in men and women Transiently elevated blood pressure is associated with increased mortality, stroke and diabetes in men and reduced mortality in women after adjustment for other risk factors
